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Pathogenic bacteria modify the lipid A portion of
their lipopolysaccharide to help evade the host innate
immune response. Modification of the negatively
charged phosphate groups of lipid A aids in resistance
to cationic antimicrobial peptides targeting the bacterial cell surface. The lipid A of Helicobacter pylori contains a phosphoethanolamine (pEtN) unit directly
linked to the 1-position of the disaccharide backbone.
This is in contrast to the pEtN units found in other
pathogenic Gram-negative bacteria, which are attached
to the lipid A phosphate group to form a pyrophosphate
linkage. This study describes two enzymes involved in
the periplasmic modification of the 1-phosphate group
of H. pylori lipid A. By using an in vitro assay system, we
demonstrate the presence of lipid A 1-phosphatase activity in membranes of H. pylori. In an attempt to identify genes encoding possible lipid A phosphatases, we
cloned four putative orthologs of Escherichia coli pgpB,
the phosphatidylglycerol-phosphate phosphatase, from
H. pylori 26695. One of these orthologs, Hp0021, is the
structural gene for the lipid A 1-phosphatase and is required for removal of the 1-phosphate group from mature lipid A in an in vitro assay system. Heterologous
expression of Hp0021 in E. coli resulted in the highly
selective removal of the 1-phosphate group from E. coli
lipid A, as demonstrated by mass spectrometry. We also
identified the structural gene for the H. pylori lipid A
pEtN transferase (Hp0022). Mass spectrometric analysis
of the lipid A isolated from E. coli expressing Hp0021
and Hp0022 shows the addition of a single pEtN group at
the 1-position, confirming that Hp0022 is responsible for
the addition of a pEtN unit at the 1-position in H. pylori
lipid A. In summary, we demonstrate that modification
of the 1-phosphate group of H. pylori lipid A requires
two enzymatic steps.

Unlike Gram-positive organisms, Gram-negative bacteria
are further guarded from their environment by an asymmetric
outer membrane that encapsulates their peptidoglycan. The
outer leaflet of the outer membrane is composed mainly of
lipopolysaccharide (LPS),1 the major surface molecule of Gram* This work was supported by National Institutes of Health Grants
K22-AI53645 (to M. S. T.), R37-GM51796 (to C. R. H. R.), and RO1GM6440 (to R. J. C). The costs of publication of this article were defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
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City, TN 37614. Tel.: 423-439-6293; Fax: 423-439-8044; E-mail:
trentms@mail.etsu.edu.
1
The abbreviations used are: LPS, lipopolysaccharide; pEtN, phos-

negative bacteria. LPS is held in the outer membrane by its
hydrophobic anchor lipid A (1, 2). Attached to lipid A are the
3-deoxy-D-manno-octulosonic acid (Kdo) sugars (Fig. 1) that act
as a bridge connecting the lipid A anchor to the core and
O-antigen (1–3). The lipid A domain is required to maintain the
integrity of the outer membrane barrier (4) and is the bioactive
component of LPS that is associated with Gram-negative septic
shock (5–7). During Gram-negative bacterial infections, lipid A
serves as one of the pathogen-associated molecular patterns
activating the innate immune system (8, 9) through the pattern
recognition receptor TLR-4 (10 –12).
The typical lipid A backbone is a ␤,1⬘-6-linked disaccharide of
glucosamine that is bisphosphorylated and multiply acylated.
In Escherichia coli, the disaccharide backbone is polyacylated
with (R)-3-hydroxymyristate at the 2-, 3-, 2⬘-, and 3⬘-positions.
The hydroxyl groups of the 2⬘- and 3⬘-linked fatty acyl chains
are further esterified with laurate (C12) and myristate (C14),
respectively (Fig. 1A) (1, 2, 5). Although a negatively charged
hexa-acylated lipid A structure is characteristic in a number of
Gram-negative animal pathogens, the lipid A structure can be
further modified.
The lipid A of Helicobacter pylori is quite unusual in that it
lacks a 4⬘-phosphate group and is tri- or tetra-acylated with
either (R)-3-hydroxystearate (C18) or (R)-3-hydroxypalmitate
(C16) (Fig. 1C) (13–15). Another unusual feature is that the C-1
hydroxyl group of the proximal glucosamine is derivatized with
a phosphoethanolamine (pEtN) residue (13–15). This is in contrast with the pEtN units of E. coli (16) (Fig. 1), Salmonella
typhimurium (17), and Neisseria meningitidis (18), which are
attached to the lipid A phosphate group to form a pyrophosphate linkage. Differences in the H. pylori lipid A structure are
reflected in its low endotoxicity compared with lipid A produced
by Gram-negative bacteria of the Enterobacteriaceae family
(14, 19, 20). Pharmacological studies have demonstrated the
importance of the phosphate groups and number of fatty acyl
chains for cytokine induction via TLR-4 (21, 22). In addition to
the low potency of H. pylori lipid A, the structure of the oligosaccharide portion of its LPS shows structural similarities to
Lewis blood group antigens in the gastric mucosa, giving rise
to a form of molecular mimicry that helps to camouflage
the bacterium (23–25). Therefore, it has been theorized that
H. pylori has evolved to have a less inflammatory LPS helping
to prolong the chronic infections seen with this organism.
A minor lipid A species found in H. pylori is both bisphosphorylated and hexa-acylated (Fig. 1B) resembling enterophoethanolamine; MES, 2-(N-morpholino)ethanesulfonic acid; IPTG,
iso-propyl-1-thio-␤-D-galactopyranoside; Kdo, 3-deoxy-D-manno-octulosonic acid; MALDI-TOF, matrix assisted laser-desorption/time
of flight.
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FIG. 1. Comparison of the chemical structures of the Kdo-lipid A domain of E. coli and the major and minor structures of H. pylori.
The covalent modifications of lipid A are indicated with dashed bonds, and lengths of the acyl chains are designated with numbers in circles. A,
the major lipid A species of E. coli is a hexa-acylated disaccharide of glucosamine that is substituted at the 1- and 4⬘-positions with phosphate and
glycosylated at the 6⬘-position with two Kdo (3-deoxy-D-manno-octulosonic acid) moieties (1, 5). In wild type K12 strains, a portion of the lipid A
contains a pyrophosphate group at the 1-position (73). The modification of phosphate moieties of E. coli lipid A are regulated by PmrA (74) and may
be substituted with L-Ara4N (red substituent) or pEtN (purple substituent) groups. In addition, the protein product of the PhoP-activated gene,
pagP, further modifies E. coli lipid A by the addition of a palmitoyl chain (blue substituent) to the hydroxyl group of the N-linked (R)-3hydroxymyristate chain on the proximal glucosamine unit of lipid A (40, 44). B, the minor lipid A species of H. pylori is similar to that seen in
E. coli but has slightly longer acyl chains and only contains one Kdo moiety (13, 14, 19). C, the major lipid A species of H. pylori is a tri- to
tetra-acylated structure that is lacking the 4⬘-phosphate group and is substituted at the C-1 position with a pEtN residue (13–15).

bacterial lipid As. We reasoned that the lipid A structure of
H. pylori is modified following the constitutive lipid A pathway
and that these modifications are not regulated given the structure of the major lipid A species shown in Fig. 1A. We report
here two proteins, Hp0021 and Hp0022, involved in the variation of the H. pylori lipid A structure.
EXPERIMENTAL PROCEDURES

Chemicals and Other Materials—[␥-32P]ATP and 32Pi were obtained
from Amersham Biosciences. Silica Gel 60 (0.25-mm) thin layer plates
were purchased from EM Separation Technology (Merck). Yeast extract
and tryptone were from Difco. Triton X-100 and bicinchoninic acid were
from Pierce. All other chemicals were reagent-grade and were purchased from either Sigma or Mallinckrodt.
Bacterial Strains and Growth Conditions—The bacterial strains and
plasmids used in this study are summarized in Table I. H. pylori strains
J99 and 26695 were obtained from the American Type Culture Collection. Primary plate cultures of H. pylori were grown from glycerol stock
on blood agar medium at 37 °C for 36 – 60 h in a microaerobic atmosphere (5% O2, 10% CO2, and 85% N2). The resultant colonies were
inoculated in Brucella broth (Invitrogen) supplemented with 10% fetal
bovine serum (Hyclone) and vancomycin (10 g/ml). Cells were grown to
an A600 of 1.0 at 37 °C under microaerobic conditions for 24 –36 h. Prior
to every experiment, confirmation of H. pylori was performed by both
Gram’s stain and urease test. E. coli was typically grown at 37 °C in
Luria-Bertani (LB) broth, which consisted of 10 g of NaCl, 10 g of
tryptone, and 5 g of yeast extract per liter (26). When required for
selection of plasmids, cells were grown in the presence of ampicillin (100
g/ml) or chloramphenicol (25 g/ml).
Recombinant DNA Technique—Plasmids were isolated by using the
Qiagen Spin Prep Kit. Custom primers were obtained from Integrated
DNA Technologies. PCR reagents were purchased from Stratagene.
PCR clean up was performed using the QIAquick PCR Purification Kit
(Qiagen). DNA fragments were isolated from gels using the QIAquick
Gel Extraction Kit (Qiagen). Restriction endonucleases, T4 DNA ligase,
and shrimp alkaline phosphatase were purchased from New England
Biolabs. All modifying enzymes were used according to the manufacturer’s instructions.
Cloning of Putative H. pylori Orthologs of E. coli pgpB and
hp0022—H. pylori orthologs of E. coli pgpB (hp0021, hp0350, hp0851,
and hp1580) and N. meningitidis lptA (60) (hp0022) were cloned into
pET21a(⫹) behind the T7lac promoter. The genes were amplified by
PCR using H. pylori strain 26695 genomic DNA as the template. The

forward and reverse primer sequences of H. pylori pgpB and lptA
orthologs are described in Table II. The forward primers contained a
clamp region, an NdeI site (Table II, underlined), and a match to the
coding strand starting at the translation initiation start site. The reverse primers were designed with a clamp region, a BamHI site (Table
II, underlined), and a match to the anti-coding strand that included a
stop codon. The PCR mixture contained 100 ng of genomic DNA template, 150 ng of each primer, 200 M of each dNTP, 100 mM Tris-HCl,
pH 8.8, 35 mM MgCl2, 250 mM KCl, and 2.5 units of Pfu DNA polymerase (Stratagene) in a reaction volume of 0.05 ml. The reaction
mixtures were subjected to a 90-s denaturation at 95 °C followed by 30
cycles of 95 °C for 60 s, 56 °C for 60 s, 72 °C for 60 s, and a final
extension for 10 min at 72 °C, using the Stratagene RoboCyler Gradient
40 PCR system. The PCR products and vectors were digested with NdeI
and BamHI, gel-purified, and ligated together. Plasmid constructs derived from pET21a(⫹) designated pHp0021, pHp0350, pHp0851,
pHp1580, and pHp0022 were transformed into XL-1 Blue cells (Stratagene) for propagation of the plasmid. The plasmids were then screened
for positive inserts and confirmed by DNA sequencing.
Additionally, hp0021 was cloned into the expression vector pWSK29
(77). The plasmid pHp0021 was subjected to restriction enzyme digest
with XbaI and XhoI. The resulting fragment containing hp0021 was
ligated into pWSK29 previously digested with XbaI and XhoI resulting
in the vector pWSHp0021.
High Copy Expression of Putative PgpB and LptA Orthologs behind a
T7lac Promoter—The H. pylori PgpB and LptA ortholog constructs
derived from pET21a(⫹) were transformed into NovaBlue(DE3) (Table
I) for overexpression of the protein. First, a single colony of E. coli
harboring either the empty vector control or the recombinant expression plasmid were inoculated into 50 ml of LB broth and grown overnight (⬃16 h) in a rotary shaker at 37 °C to A600 ⬃1. The appropriate
amount of overnight culture was used to inoculate 200 ml of fresh LB
broth with an initial 〈600 of 0.05. Prior to induction with 1 mM IPTG,
cells were allowed to reach mid-log phase of growth (〈600 ⬃0.6). After
induction with IPTG, the cells were left shaking for an additional 4 h.
To determine the level of protein expression, membrane proteins
were isolated (see below), separated by SDS-PAGE, and stained with
Coomassie gel code blue staining reagent (Pierce). Unfortunately, expression of Hp0021, Hp0350, Hp0851, Hp1580, or Hp0022 in E. coli
NovaBlue(DE3) did not result in any distinct protein bands (data
not shown).
Cloning of Putative PgpB Orthologs into a Low Copy Expression
Vector—PCR-amplified pgpB orthologs (hp0021, hp0350, hp0851, and
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TABLE I
Bacterial strains and plasmids used in this study

Strain or plasmid

Strains
H. pylori
J99
26695
E. coli
W3110
W3110A
WD2
XL-1 Blue
Nova F⫺
NovaBlue(DE3)
HSM174(DE3)
BLR(DE3)pLysS
Plasmids
pET21a(⫹)
pETCoco-2
pETDuet-1
pHp0021
pHp0350
pHp0851
pHp1580
pHp0022
pHp0021coco
pHp0350coco
pHp0851coco
pHp1580coco
pHp0021duet
pHp0022duet
pHp0021/Hp0022
pWSK29
pWSHp0021
pMsbB
pHtrB

Genotype or description

Source or Reference

Wild type
Wild type

ATCC 700824
ATCC 700392

Wild type, F⫺, ⫺
Wild type, F⫺, ⫺, aroA::Tn10
W3110, aroA::Tn10 msbA (A270T)
recA1 endA1 gyrA96thi-1 hsdR17 supE44 relA1 lac 关F⬘ proAB
lacIqZ⌬M15::Tn10 (TetR)兴
F⫺, endA1 hsdR17(rK12⫺ mK12⫹) supE44 thi-1 recA1 gyrA96 relA1 lac
endA1 hsdR17(rK12⫺ mK12⫹) supE44 thi-1 recA1 gyrA96 relA1 lac (DE3)
关F⬘ proAB lacIqZ⌬M15::Tn10 (TetR)兴
F⫺ recA1 hsdR (rK12⫺ mK12⫹) (DE3) Rif R
F⫺ ompT hsdSB (rB⫺ mB⫺) gal dcm (DE3) ⌬(srl-recA)306:: Tn10 pLysS,
(TetR, CamR)

E. coli Genetic Stock Center (Yale)
71
72
Stratagene

Expression vector containing a T7 promoter, AmpR
Expression vector containing a T7 promoter, and two origins of
replication control the single-copy (oriS) and medium-copy (oriV),
AmpR
Expression vector containing two multiple cloning sites (MCS), each of
which is preceded by a T7lac promoter, lacI, AmpR
pET21a (⫹) containing hp0021
pET21a (⫹) containing hp0350
pET21a (⫹) containing hp0851
pET21a (⫹) containing hp1580
pET21a (⫹) containing hp0022
pETCoco-2 containing hp0021
pETCoco-2 containing hp0350
pETCoco-2 containing hp0851
pETCoco-2 containing hp1580
pETDuet-1 containing hp0021
pETDuet-1 containing hp0022
pETDuet-1 containing both hp0021 and hp0022
Low-copy expression vector, Ampr
pWSK29 containing hp0021
pET21a (⫹) containing msbB (lpxL)
pET21a (⫹) containing htrB (lpxM)

Novagen
Novagen

TABLE II
Oligonucleotides
Name

Sequence

U-hp0022-NdeI
L-hp0022-BamHI
U-hp0021-NdeI
L-hp0221-BamHI
U-hp0350-NdeI
L-hp0350-BamHI
U-hp0851-NdeI
L-hp0851-BamHI
U-hp1580-NdeI
L-hp1580-BamHI
U-hp0021coco-NsiI
L-hp0021coco-BstBI
U-hp0350coco-NsiI
L-hp0350coco-BstBI
U-hp0851coco-NsiI
L-hp0851coco-BstBI
U-hp1580coco-NsiI
L-hp1580coco-BstBI
htrBUpper
htrBLower

5⬘-GCGCGCCATATGTTGGCATCATTATTCCAT-3⬘
5⬘-GCGCGCGGATCCTTACTCTTTTTTGTGTTT-3⬘
5⬘-GCGCGCCATATGAAAAAATTCTTATTTAAA-3⬘
5⬘-GCGCGCGGATCCTTAAGGCTTTTTGGGGCT-3⬘
5⬘-GCGCGCCATATGCTGAAAATTCTTTCAAA-3⬘
5⬘-GCGCGCGGATCCTTAGATCTTTTGAAACAC-3⬘
5⬘-GCGCGCCATATGTATTTGACAGAACAATC-3⬘
5⬘-GCGCGCGGATCCTTATTGATTATAAGGGCG-3⬘
5⬘-GCGCGCCATATGCTATTTAATGGGCTATGC-3⬘
5⬘-GCGCGCGGATCCTTACCATTGATAAGAAAA-3⬘
5⬘-GCGCGCCATGCATAAAAAATTCTTATTTAAA-3⬘
5⬘-GCGCGCCTTCGAATTAAGGCTTTTTGGGGCT-3⬘
5⬘-GCGCGCCATGCATGCTGAAAATTCTTTCAAA-3⬘
5⬘-GCGCGCCTTCGAATTAGATCTTTTGAAACAC-3⬘
5⬘-GCGCGCCATGCATGTATTTGACAGAACAATC-3⬘
5⬘-GCGCGCCTTCGAATTATTGATTATAAGGGCG-3⬘
5⬘-GCGCGCCATGCATCTATTTAATGGGCTATGC-3⬘
5⬘-GCGCGCCTTCGAATTACCATTGATAAGAAAA-3⬘
5⬘-GCGCGCCATATGATGACGAATCTACCC-3⬘
5⬘-GCGGCGGGATCCTTAATAGCGTGAAGG-3⬘

hp1580) from H. pylori strain 26695 were cloned into pETCoco-2 for low
copy replication and protein expression. The forward and reverse
primer sequences of pgpB orthologs cloned into pETCoco-2 are described in Table II. The forward primers for pgpB orthologs contained a
clamp region, an NsiI site (Table II, underlined), and a match to the
coding strand beginning at the translation initiation start site. The
reverse primers were designed with a clamp region, a BstBI site (Table
II, underlined), and a match to the anti-coding strand that included a
stop codon. Amplification was carried out as mentioned previously. The
PCR products and vector were digested with NsiI and BstBI, gelpurified, and ligated together. Plasmid constructs derived from pETCoco-2 designated pHp0021coco, pHp0350coco, pHp0851coco, and

Novagen
Novagen
Novagen
Novagen

Novagen
This
This
This
This
This
This
This
This
This
This
This
This
77
This
37
This

work
work
work
work
work
work
work
work
work
work
work
work
work
work

pHp1580coco were transformed into NovaF⫺ cells (Novagen) for plasmid propagation. All constructs derived from pETCoco-2 were maintained in the single copy state with LB broth containing ampicillin (50
g/ml) and 0.2% D-glucose at all times to ensure maximum stability,
except during culturing for plasmid DNA isolation. Plasmid propagation of pETCoco-2-derived constructs was typically grown by inoculating a single colony of E. coli containing an empty or recombinant
plasmid into 5 ml of LB broth supplemented with ampicillin and 0.2%
glucose and grown overnight (⬃16 h) in a rotary shaker (250 rpm) at
37 °C. The overnight cultures were diluted to 1:50 with fresh LB broth
containing ampicillin without glucose because the sugar prevents amplification of the plasmid. Cells were induced with 0.01% L-arabinose for
plasmid replication at an A600 of 0.4. The cells were allowed to grow for
an additional 4 h prior to harvest for plasmid purification. Plasmid
constructs were then screened for positive inserts, confirmed by DNA
sequencing, and transformed into E. coli K12 strain HMS174(DE3) cells
(Novagen) for low copy expression.
Low Copy Expression of Putative Orthologs of PgpB—Low copy expression of pETCoco-2 derivatives was performed according to the instructions described by Novagen. Typically, a single colony of E. coli
harboring either the empty vector control or the recombinant expression plasmid was inoculated into 5 ml of LB broth supplemented with
ampicillin and 0.2% glucose and grown overnight at 37 °C. Overnight
cultures were then used to inoculate 20 ml of fresh LB broth containing
ampicillin with or without glucose at an initial A600 of 0.05. At mid-log
phase of growth, the cells were induced with 0.5 mM IPTG and allowed
to grow for an additional 3 h before harvesting.
Isolation and Analysis of Lipid A Species from 32Pi-Labeled Cells—
Cells containing pETCoco-2 derivatives were grown as described above.
Upon induction at mid-log phase with IPTG, the cells were labeled
uniformly with 2.5 Ci/ml 32Pi for an additional 3 h at 37 °C. Bacteria
were collected using a clinical centrifuge and washed with 5 ml of
phosphate-buffered saline, pH 7.4. To extract the 32P-labeled phospholipids, the cell pellet was resuspended in 3 ml of a single-phase Bligh/
Dyer mixture (27), consisting of chloroform/methanol/water (1:2:0.8,
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v/v). After mixing and incubating for 30 min at room temperature, the
insoluble residue, containing the 32P-labeled lipid A still covalently
bound to LPS, was recovered by centrifugation. The residue was subjected to hydrolysis at 100 °C in 12.5 mM sodium acetate buffer, pH 4.5,
in the presence of 1% SDS to cleave the Kdo-lipid A linkage (16, 28). The
32
P-labeled lipid A species were recovered by two-phase Bligh/Dyer
extraction (16, 28) and spotted onto a Silica Gel 60 TLC plate (10,000
cpm/lane). The plate was developed in the solvent chloroform, pyridine,
88% formic acid, water (50:50:16:5, v/v). The plate was dried and exposed to a PhosphorImager Screen overnight to visualize the resolved
32
P-lipid A species.
Cloning and Expression of H. pylori Hp0021 and Hp0022 in a Dual
Expression System—The plasmid constructs, pHp0021 and pETDuet-1,
were subjected to restriction enzyme digest with NcoI and BamHI. The
resulting Hp0021 DNA fragment was isolated and ligated into the
multiple cloning site 1 of pETDuet-1 to derive the plasmid construct
pHp0021duet. In addition, the plasmid constructs pHp0022, pETDuet-1, and pHp0021duet were subjected to restriction enzyme digested with NdeI and XhoI. The resulting Hp0022 DNA fragment was
ligated into the MSC2 of both pETDuet-1 and pHp0021duet vectors to
generate the plasmid constructs pHp0022duet and pHp0021/Hp0022,
respectively. All of the plasmids derived from pETDuet-1 were transformed into XL-1 Blue cells for propagation of the plasmids, screened
for positive inserts, and confirmed by DNA sequencing. The plasmids
pHp0021duet, pHp0022duet, or pHp0021/Hp0022 were then transformed into the E. coli expression strain NovaBlue(DE3) and overexpressed as described previously.
Cloning and Expression of the E. coli Late Acyltransferases, LpxL and
LpxM, behind a T7lac Promoter—The lpxL structural gene was obtained by PCR using W3110 genomic DNA as the template. The lpxM
structural gene was cloned and the protein overexpressed as described
previously (29). Primer sequences for lpxL are described in Table II. The
lpxL PCR product was digested with NdeI and BamHI and ligated into
the similarly digested vector pET21a(⫹). The resulting plasmid, pHtrB,
was transformed into BLR(DE3)/pLysS cells (Novagen) for protein expression. Cells were grown in LB broth at 37 °C to A600 of ⬃0.6, followed
by induction with 1 mM IPTG and further incubation at 37 °C for an
additional 4 h.
Preparation of Cell-free Extracts, Double-spun Cytosol, and Washed
Membrane—Typically, 500 ml of H. pylori or 200 ml of E. coli cultures
were grown to an 〈600 of 1.0 at 37 °C and harvested by centrifugation at
6,000 ⫻ g for 30 min. All samples were prepared at 4 °C. Cell-free
extract, double-spun cytosol, and washed membranes were prepared as
described previously (30) and were stored in aliquots at ⫺20 °C. Protein
concentration was determined by the bicinchoninic acid method (31),
using bovine serum albumin as the standard.
Preparation of Radiolabeled Substrate—The substrate 4⬘-32P-lipid
IVA was generated from 100 Ci of [␥-32P]ATP and the tetraacyldisaccharide 1-phosphate lipid acceptor, using the overexpressed 4⬘kinase present in membranes of E. coli BLR(DE3)/pLysS/pJK2 (30, 32,
33), as described previously (30, 33). Kdo2-4⬘-32P-lipid IVA was prepared
by adding purified E. coli Kdo transferase (WaaA) immediately after
the 4⬘-kinase, as described previously (33, 34). To prepare Kdo2-4⬘-32Plipid A (dilauroyl-Kdo2-4⬘-32P-lipid IVA), lauroyl-acyl carrier protein
and E. coli overexpressed LpxL and LpxM (29) membranes were used in
tandem with the Kdo transferase reaction under the following conditions: 50 mM Hepes, pH 7.5, 0.1% Triton X-100, 50 mM NaCl, 50 mM
MgCl2, 0.1 mg/ml bovine serum albumin, 13.3 M lauroyl-acyl carrier
protein, and 0.05 mg/ml BLR(DE3)/pLysS/pMsbB and BLR(DE3)/
pLysS/pHtrB membranes. Once the reaction was complete, the substrate was isolated as described previously (33).
Assay of the 1-Phosphatase—The 1-phosphatase activity from
Hp0021 was assayed under optimized conditions in a 10-l reaction
mixture containing 50 mM MES, pH 6.0, 0.2% Triton X-100, and either
5 M 4⬘-32P-lipid IVA, Kdo2-4⬘-32P-lipid IVA, or Kdo2-4⬘-32P-lipid A (each
at ⬃3000 –5000 cpm/nmol) as the substrate. Washed membranes
(0.005–1.0 mg/ml) were employed as the enzyme source, as indicated.
Dephosphorylation reactions were incubated at 30 °C for the indicated
times. Enzymatic reactions were terminated by spotting 4.5-l portions
of the mixtures onto Silica Gel 60 TLC plates, and the plate was dried
under a cool air stream for 20 min.
When 4⬘-32P-lipid IVA was employed as the substrate, reaction products were separated using the solvent chloroform, pyridine, 88% formic
acid, water (50:50:16:5, v/v). For reactions containing either Kdo2-4⬘32
P-lipid IVA or Kdo2-4⬘-32P-lipid A as the substrate, the TLC plates
were developed in the solvent chloroform, pyridine, 88% formic acid,
water (30:70:16:10, v/v). After drying and overnight exposure of the
plate to a PhosphorImager Screen, the product formation was detected
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and analyzed using a Bio-Rad Molecular Imager PhosphorImager
equipped with Quantity One Software. The enzyme activity was calculated by determining the percentage of the substrate converted
to product.
Separation of Inner and Outer Membranes—Membranes isolated
from E. coli strain NovaBlue(DE3)/pHp0021 were separated by isopycnic sucrose gradient centrifugation. First, washed membranes
were prepared as described above and were resuspended in 10 mM
Hepes, pH 7.0, containing 0.05 mM EDTA at a protein concentration
of 1–3 mg/ml. Membranes (2.2 ml) were layered onto a seven-step
gradient, as described previously (35, 36), and subjected to ultracentrifugation at 35,000 rpm in a Beckman SW41 rotor for 19 h at 4 °C.
The gradient was collected in ⬃0.5-ml fractions. Each fraction was
then assayed for NADH oxidase, as the inner membrane marker, and
for phospholipase A, as the outer membrane marker, as described
previously (28). The amount of protein in each fraction was determined using the bicinchoninic acid assay (31). Each fraction was also
assayed for 1-phosphatase activity using the standard conditions
described above.
Large Scale Isolation of Lipid A from E. coli Cells Expressing
H. pylori Hp0021 and Hp0022—Cultures of E. coli strain NovaBlue(DE3) were grown in 1 liter of LB medium at 37 °C containing
either pDuet-1, pHp0021duet, pHp0022duet, or pHp0021/Hp0022.
The cultures were allowed to reach A600 ⬃0.6 prior to induction with
1 mM IPTG and further incubated for an additional 4 h at 37 °C. Cells
were harvested by centrifugation at 6000 ⫻ g for 15 min and washed
once with phosphate-buffered saline (37). The final cell pellets were
resuspended in 40 ml of phosphate-buffered saline. Lipid A was
released from cells and purified as described previously (16, 38) and
stored frozen at ⫺20 °C.
Purification of the 1-Phosphatase Reaction Product Generated in
Vitro from Kdo2-Lipid A—A large scale 1-phosphatase reaction mixture
(20 ml) was prepared by assembling the following components: 50 mM
MES, pH 6.0, 0.25% Triton X-100, 50 M of Kdo2-lipid A (39), and 0.3
mg/ml membrane proteins from NovaBlue(DE3)/pHp0021 (39). The reaction was initiated by the addition of the enzyme and incubated at
30 oC for 3 h. The reaction mixture was then converted into a two-phase
Bligh-Dyer system consisting of chloroform, methanol, 0.05 M HCl (2:
2:1.8, v/v). The phases were separated by centrifugation at 4000 ⫻ g for
10 min. The lower phase was removed, and the resulting upper phase
was extracted a second time by the addition of lower phase from a fresh
two-phase acidic Bligh-Dyer system. The lower phases were pooled, and
pyridine (1 drop/4 ml) was added to neutralize the minor amount of HCl
carried over during the extraction process. The sample was dried by
rotary evaporation, dissolved in 5 ml of chloroform/methanol/water
(2:3:1, v/v), and applied to a 1-ml DE52 cellulose column equilibrated
with the same solvent mixture. Following sample loading, the column
was washed with 5 column volumes of chloroform/methanol/water (2:
3:1, v/v). The bound phospholipids and lipid A were eluted with 1-ml
steps of chloroform/methanol/ammonium acetate (2:3:1, v/v), with increasing ammonium acetate concentrations of 60, 120, 240, and 480 mM
successively in the aqueous component. For each step elution, 1-ml
fractions were collected. The presence of lipids was determined by
spotting 10 l of each fraction onto a TLC plate followed by developing
in chloroform, pyridine, 88% formic acid, water (30:70:16:10, v/v). After
drying, lipids were visualized by spraying the plate with 10% sulfuric
acid in ethanol and then charring. All fractions containing 1-dephosphorylated-Kdo2-lipid A were pooled and converted to a two-phase
Bligh/Dyer mixture by addition of appropriate amounts of chloroform
and water. The lower phase was dried under a stream of N2 and stored
at ⫺20 °C.
Mass Spectrometry of Lipid A Species—Mass spectra of the purified
lipids were acquired in the negative and positive linear mode using a
matrix-assisted laser desorption-ionization/time of flight (MALDI-TOF)
mass spectrometer (AXIMA-CFR, Kratos Analytical, Manchester, UK)
equipped with a nitrogen laser (337 nm). The instrument was operated
using 20-kV extraction voltage and time-delayed extraction, providing a
mass resolution of about ⫾1 atomic mass units for compounds with Mr
⬃2000. Each spectrum represented the average of 100 laser shots.
Saturated 6-aza-2-thiothymine in 50% acetonitrile and 10% tribasic
ammonium citrate (9:1, v/v) served as the matrix in negative and
positive modes. The samples were dissolved in chloroform/methanol
(4:1, v/v) and deposited on the sample plate followed by an equal portion
of matrix solution (0.3 l). The sample was dried at 25 °C prior to
mass analysis.
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FIG. 2. Detection of 1-phosphatase activity in membranes of
wild type strains of H. pylori. Membranes from either E. coli wild
type strain W3110 or H. pylori wild type strains (26695 and J99) were
assayed for 1-phosphatase activity using assay conditions described
under “Experimental Procedures.” The protein concentration was 1.0
mg/ml, and assays were carried out for both 30 min (A) and 3 h (B) at
30 °C. Each reaction contained 5 M 4⬘-32P-lipid IVA substrate. Reaction
products were separated by TLC and detected with PhosphorImager
analysis. Removal of the 1-phosphate group was indicated by conversion of the 4⬘-32P-lipid IVA substrate to a faster migrating species (26).
RESULTS

1-Phosphatase Activity in Membranes of Wild Type Virulent
Strains of H. pylori—Membranes from virulent strains of
H. pylori were isolated and assayed with 4⬘-32P-lipid IVA, a key
lipid A precursor substrate, for 1-phosphatase activity. As
shown in Fig. 2, membranes from both H. pylori strains 26695
and J99 display 1-phosphatase activity, denoted as 1-dephospho-4⬘-32P-lipid IVA (Fig. 2, lanes 3, 4, 6, and 7). Removal of the
1-phosphate group from 4⬘-32P-lipid IVA increases the hydrophobicity of the lipid substrate, resulting in a faster migrating
lipid species when analyzed by TLC in the solvent chloroform,
pyridine, 88% formic acid, and water (50:50:16:5, v/v). The
phosphatase activity seen in Fig. 2 is not a result of 4⬘-phosphatase activity, because 4⬘-phosphatase activity would catalyze the release of inorganic 32Pi from the 4⬘-position of lipid A
when analyzed by TLC. However, a slower migrating species,
lipid IVB, was detected from membranes of wild type E. coli
strain W3110 after 3 h at 30 °C (Fig. 2, lane 5). Lipid IVB is
generated by the addition of a palmitate chain to the amidelinked ␤-hydroxmyristate residue at position 2 of lipid IVA (40,
41) that is catalyzed by the E. coli outer membrane protein,
PagP (40, 42– 44). The lipid A of E. coli normally contains
phosphate groups at both the 1- and 4⬘-positions (5) and is not
dephosphorylated prior to the addition of a pEtN or L-Ara4N.
As a result, membranes from wild type E. coli strain W3110 do
not show 1-phosphatase activity (Fig. 2, lanes 2 and 5).
Identification of the H. pylori 1-Phosphatase (Hp0021) from
Putative Orthologs of E. coli PgpB—Recently, Karbarz et al.
(46) identified LpxE, a phosphatase that selectively removes
the 1-phosphate group of Rhizobium leguminosarum lipid A.
Discovery of LpxE revealed that it is distantly related to the
membrane-bound phosphatidylglycerol phosphatase in E. coli
(PgpB) (45– 48). Therefore, we searched the COG protein data
base (49 –52) using E. coli PgpB to identify possible H. pylori

FIG. 3. Assay for 1-phosphatase activity from E. coli membranes overexpressing putative H. pylori PgpB homologs
(Hp0021, Hp1580, Hp0851, and Hp0350). Membranes from E. coli
K12 strain, NovaBlue(DE3), containing either the vector control or the
indicated hybrid plasmids were assayed for 1-phosphatase activity using 4⬘-32P-lipid IVA. The protein concentration was 0.05 mg/ml, and
assays were carried out for 1 h at 30 °C with 5 M 4⬘-32P-lipid IVA
substrate. The products were separated by TLC and detected with
PhosphorImager analysis.

lipid phosphatases. COG0671 contains four putative orthologs
of PgpB in H. pylori strain 26695, designated Hp0021, Hp0350,
Hp0851, and Hp1580. The H. pylori PgpB orthologs were examined for 1-phosphatase activity by expressing the putative
lipid phosphatases in the E. coli K12 strain NovaBlue(DE3).
Membranes isolated from NovaBlue(DE3) containing either
pET21a(⫹) (vector control), pHp0021, pHp1580, pHp0851, or
pHp0350 were assayed with 4⬘-32P-lipid IVA for 1-phosphatase
activity (Fig. 3). NovaBlue(DE3) membranes expressing
Hp0021 displayed a considerable amount of 1-phosphatase activity (Fig. 3, lane 3) as compared with membranes from cells
containing the vector control (Fig. 3, lane 2). In contrast, NovaBlue(DE3) membranes expressing either Hp0350 or Hp1580
(Fig. 3, lanes 4 and 5) did not demonstrate any 1-phosphatase
activity. NovaBlue(DE3) membranes expressing Hp0851 (Fig.
3, lane 6) did display minor amounts of 1-phosphatase activity;
however, further examination revealed that the activity was
nonspecific (see below).
Assay Conditions and Catalytic Properties of Hp0021—The
Hp0021 protein is predicted to be 190 amino acids long and
contains three membrane-spanning regions (see sosui.proteome.bio.tuat.ac.jp/sosuiframe0.html). The 1-phosphatase activity of Hp0021 is absolutely dependent on the presence of the
nonionic detergent, Triton X-100, with optimal activity at 0.2%
detergent. The pH optimum is 6.0, but significant activity is
observed from pH 5.5 to 8.0. Divalent cations are not required,
and EDTA has no effect on activity. The substrate specificity of
Hp0021 is relatively broad (Fig. 4A) and does not require the
Kdo moiety or complete acylation for activity, as indicated by
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FIG. 5. Lipid A composition in E. coli K12 strains expressing
putative H. pylori PgpB orthologs. The 32P-labeled lipid A species
from HMS174(DE3) containing the vector control (pETcoco-2) or the
indicated hybrid plasmids were isolated as described under “Experimental Procedures.” The labeled lipid A species were separated by TLC
using the solvent chloroform, pyridine, 88% formic acid, water (50:50:
16:5, v/v) and visualized by PhosphorImaging. The presence of 1-dephosphorylated-lipid A from HMS174(DE3) expressing Hp0021 is indicated. A small amount of 1-dephosphorylated-lipid A may arise as a
decomposition product during hydrolysis of the Kdo linkage at pH 4.5 at
100 °C (16, 17, 36). A reduced amount of 32P-labeled lipid A was isolated
from bacteria expressing Hp0851 and Hp0350 because of toxic effects
upon protein expression.
FIG. 4. Substrate specificity and time dependence of the
H. pylori lipid A 1-phosphatase. A, the 1-phosphatase activity of
NovaBlue(DE3) membranes expressing Hp0021 was assayed under
standard conditions described under “Experimental Procedures” with
either 5 M 4⬘ 32P-lipid IVA, Kdo2-4⬘ 32P-lipid IVA, or Kdo2-4⬘ 32P-lipid A.
Protein concentrations at 0.05 mg/ml from NovaBlue(DE3)/pHp0021
membranes served as the enzyme source. Reaction products were separated by TLC as described under “Experimental Procedures” and
subjected to PhosphorImager analysis. B, the 1-phosphatase activity of
Hp0021 was assayed under standard conditions with 5 M 4⬘ 32P-lipid
IVA. Membranes from NovaBlue(DE3) expressing Hp0021 at the indicated concentrations served as the enzyme source. Reaction products
were separated by TLC as described under “Experimental Procedures”
and subjected to PhosphorImager analysis.

the higher amount of activity with 4⬘-32P-lipid IVA than with
either Kdo2-4⬘-32P-lipid IVA or Kdo2-4⬘-32P-lipid A. Formation
of the 1-dephosphorylated reaction products is linear with both
protein concentration and time. As shown in Fig. 4B, the 1-dephosphorylation of 5 M 4⬘-32P-lipid IVA by 0.01 mg/ml NovaBlue(DE3)/pHp0021 membranes is linear with time for ⬃40
min at 30 °C. Next, the complete 1-dephosphorylation of 5 M
4⬘-32P-lipid IVA is seen after 1.5 h when using 0.05 mg/ml of
membrane protein (Fig. 4A). Overall, the H. pylori lipid A
1-phosphatase is a very stable enzyme having a specific activity
of ⬃170 nmol/min/mg with lipid IVA as the substrate and
E. coli membranes overexpressing Hp0021 as the enzyme
source.
Low Copy Expression of H. pylori PgpB Orthologs in E. coli—
Assay of E. coli membranes expressing Hp0851 showed minor
amounts of 1-phosphatase activity (Fig. 3, lane 6). To confirm
that Hp0021 functions as a lipid A phosphatase and to ensure
that Hp0851 phosphatase activity was nonspecific, we isolated
the lipid A from E. coli expressing the individual supposed H.
pylori PgpB orthologs. The putative lipid phosphatases were
cloned into the low copy expression vector pETCoco-2 to generate
the following plasmids: pHp0021coco, pHp1580coco, pHp0851coco, and pHp0350coco. A low copy expression system was utilized

to avoid nonspecific phosphatase activity generated from high
levels of protein expression. Cultures of the E. coli K12 strain
HMS174(DE3) containing one of the pETCoco-2 derived plasmids
were labeled with 32Pi, and the lipid A fraction was isolated to
determine possible modifications in vivo.
HMS174(DE3) containing the pETcoco-2 vector control produced the typical 32P-labeled lipid A species seen in wild type
E. coli K12, 1,4⬘-bisphosphate lipid A, and 1-pyrophosphate
lipid A. The latter contains a pyrophosphate at the 1-position of
the disaccharide (Fig. 1) and represents approximately onethird of the lipid A found in E. coli grown on nutrient broth (16,
28). Low copy expression of Hp0021 resulted in the production
of only 1-dephosphorylated lipid A (Fig. 5, lane 2) illustrating
that Hp0021 functions as a lipid A phosphatase. 32P-Labeled
lipid A fractions isolated from cells containing pHp0350coco,
pHp0851coco, and pHp1580coco did not contain any significant
amount of 1-dephosphorylated lipid A species (Fig. 5, lanes
3–5). The minor amount of 1-dephosphorylated lipid seen in
Fig. 5, lanes 3–5, arises as a decomposition product during mild
acid hydrolysis at 100 °C used to free lipid A from LPS (16, 17,
36). An increase in Hp0851 expression by increasing copy number of the pHp0851coco plasmid did not result in any production of dephosphorylated lipid A species (data not shown),
confirming that only Hp0021 functions as a lipid A 1-phosphatase in vivo. Bacteria showed normal growth during expression
of either Hp0021 or Hp1580. However, induction of Hp0851
and Hp0350 resulted in a decrease in growth rate (data not
shown). Although we were unable to isolate as much 32Plabeled lipid A from cells expressing Hp0851, it appeared that
HMS174(DE3) containing pHp0851coco did not produce the
1-pyrophosphorylated lipid A species.
MALDI-TOF Mass Spectrometry of the 1-Phosphatase Reaction Product—To confirm that hp0021 is the structural gene for
H. pylori lipid A 1-phosphatase, the reaction product utilizing
mature Kdo2-lipid A as the substrate was analyzed by MALDITOF mass spectrometry in the negative mode. MALDI-TOF
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FIG. 6. MALDI-TOF mass spectrometry of the 1-phosphatase reaction product generated from Kdo2-lipid A. The reaction product
generated from incubation of hexa-acylated Kdo2-lipid A with NovaBlue(DE3)/pHp0021 membranes was purified by DEAE-cellulose chromatography as described under “Experimental Procedures.” The spectra shown in A is that of the starting Kdo2-lipid A substrate, and the spectra shown
in B shows the resulting 1-dephosphorylated reaction product, 1-dephosphorylated-Kdo2-lipid A. Both spectra were acquired in the negative
ion mode.

mass spectrometry of the initial substrate E. coli Kdo2-lipid A
revealed a major ion peak at m/z 2238.7 atomic mass units with
additional minor ions at m/z 2019.3 and 1798.7 atomic mass
units (Fig. 6A). The signal at m/z 2238.7 atomic mass units is
interpreted as [M ⫺ H]⫺ of the predominant hexa-acylated
Kdo2-lipid A 1,4⬘-bisphosphate molecule (Fig. 6A), characteristic of E. coli K12. The peaks at m/z 2019.3 and 1798.7 atomic
mass units are interpreted as [M ⫺ H-Kdo]⫺ and [M ⫺ HKdo2]⫺, respectively, and correspond to the loss of the labile
Kdo moiety during mass spectrometry (Fig. 6A). MALDI-TOF
mass spectrometry of the Hp0021 reaction product revealed a
predominant peak at m/z 2158.4 atomic mass units confirming
the enzymatic removal of the 1-phosphate group (Fig. 6B) from
the Kdo2-lipid A substrate. Again, the minor peaks at m/z
1938.9 and 1718.5 arise from the loss of either one or two Kdo
moieties from the 1-dephosphorylated reaction product, respectively (Fig. 6B).
Identification of the Structural Gene Encoding the H. pylori
Lipid A pEtN Transferase (Hp0022)—We have demonstrated
that Hp0021 is responsible for removing the 1-phosphate group
from the proximal glucosamine of lipid A. However, the major
lipid species of H. pylori has a pEtN unit directly linked to the
1-position of the disaccharide backbone (Fig. 1C). This suggests
that the modification of H. pylori lipid A at the 1-position also
requires a lipid A pEtN transferase. Recently, Cox et al. (53)
identified NMB1638, renamed LptA, as a pEtN transferase
specific for N. meningitidis lipid A based upon loss of pEtN
from lipid A in an lptA mutant. Also, it has been shown in vitro
that E. coli YjdB (EptA) transfers pEtN to E. coli lipid A
precursors (54). Examination of the COG data base using either N. meningitidis NMB1638 or E. coli YjdB to search for
orthologs in H. pylori strain 26695 revealed two possible orthologs designated Hp0022 and Hp1417m.
We decided to investigate Hp0022 as the possible H. pylori
lipid A pEtN transferase primarily because of its homology to

LptA (E value ⬍10⫺48 using BLASTp) and also because its
structural gene is located in a putative operon with hp0021 in
the H. pylori genome. Hp0022 is estimated to be 521 amino
acids long and is predicted to contain multiple membranespanning regions (see sosui.proteome.bio.tuat.ac.jp/sosuiframe0.
html). Membranes isolated from NovaBlue(DE3) containing
either pET21a(⫹) or pHp0022 were assayed for pEtN transferase activity using the substrates 4⬘-32P-lipid IVA, Kdo2-4⬘-32Plipid IVA, and Kdo2-4⬘-32P-lipid A. Assaying Hp0022 with lipid
A precursor substrates that were still phosphorylated at the
1-position did not demonstrate any 1-pEtN transferase activity
when analyzed by TLC (data not shown). These data suggest
that the activity of Hp0022 may require a lipid A substrate that
is initially dephosphorylated at the 1-position prior to the addition of a pEtN.
To demonstrate that the 1-phosphate group modification of
H. pylori may require two enzymatic steps, we developed a dual
protein expression system. The target proteins were expressed
under the control of two separate T7lac promoters by cloning
hp0021 and hp0022 into two separate multiple cloning sites of
pETDuet-1 giving the plasmid pHp0021/Hp0022. In addition,
Hp0021 and Hp0022 were individually cloned into pETDuet-1
giving the plasmids pHp0021duet and pHp0022duet. Separation of 32P-labeled lipid A species from NovaBlue(DE3) containing the vector pHp0021duet clearly demonstrates again that
Hp0021 is responsible for the presence of 1-phosphatase-modified lipid A species (Fig. 7, lane 2). However, cells containing
the pDuet-1 vector control contained the typical 1,4⬘-bisphosphorylated and the 1-pyrophosphorylated E. coli lipid A species. As demonstrated in Fig. 7, lane 3, 32P-labeled lipid A
species isolated from NovaBlue(DE3) containing pHp0022duet
were similar to those found in cells containing the pDuet-1
vector control suggesting that Hp0022 alone does not modify
E. coli lipid A. 32P-Labeled lipid A species isolated from NovaBlue (DE3) containing the dual expression construct, pHp0021/
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FIG. 7. Dual expression of Hp0021
and Hp0022 in E. coli results in the
formation of 1-pEtN-lipid A species.
The 32P-labeled lipid A species from the
indicated strains were isolated as described under “Experimental Procedures,” separated by TLC using the solvent chloroform, pyridine, 88% formic
acid, water (50:50:16:5, v/v), and visualized by PhosphorImaging. A small
amount of 1-dephosphorylated-lipid A
may arise as a decomposition product
during hydrolysis of the Kdo linkage at
pH 4.5 at 100 °C (16, 17, 36). The structure of the lipid A species labeled as
1-pEtN-Lipid A was verified by mass
spectrometry (Fig. 9D).

Hp0022, revealed the following three lipid species: 1,4⬘bisphosphorylated lipid A, 1-dephosphorylated lipid A, and
lipid A containing a pEtN group at the C-1 position (see Fig. 8).
Removal of the 1-phosphate group from 1,4⬘-bisphosphorylated
lipid A followed by the addition of 1-pEtN unit generated a lipid
species that migrates in a similar fashion to 1-pyrophosphate
lipid A (Fig. 7, lane 4). Therefore, mass spectrometry was
employed to differentiate between the two lipid species and to
confirm that hp0022 encodes for a pEtN transferase acting
after 1-dephosphorylation of H. pylori lipid A.
The lipid A of E. coli strain NovaBlue(DE3) containing either
pETDuet-1, pHp0021duet, pHP0022duet, or pHp0021/Hp0022
was isolated and analyzed by MALDI-TOF mass spectrometry.
The lipid A of NovaBlue(DE3) containing the control vector,
pETDuet-1, consisted primarily of the hexa-acylated bisphosphate species with MALDI-TOF analysis resulting in a major
peak at m/z 1798.4 (16, 38) (Fig. 8A). Mass spectrometry analysis of NovaBlue(DE3) containing the control vector also revealed the presence of hexa-acylated pyrophosphate (data not
shown). Similar results were seen upon examination of the
lipid A fraction of NovaBlue(DE3) expressing Hp0022 (Fig. 8C).
As expected, expression of Hp0021 resulted in the loss of a
single phosphate unit from lipid A (Fig. 8B), as indicated by
[M ⫺ H]⫺ at m/z 1719.0 in the negative mode. Furthermore, the
positive ion spectrum showed the presence of B1⫹ ion at m/z
1087.3 indicating that the distal portion of the lipid A was not
dephosphorylated (Fig. 8E). Mass spectrometry analysis of
lipid A isolated from cells overexpressing both Hp0021 and
Hp0022 demonstrated two ion peaks at m/z 1719.0 and 1840.9
atomic mass units in the negative mode (Fig. 8D). The ion peak
at m/z 1719.0 corresponds to the loss of a phosphate group of

lipid A. However, the ion peak at m/z 1840.9 correlates to the
addition of a pEtN group that is interpreted as the addition of
a pEtN unit to previously dephosphorylated lipid A. Therefore,
based on these data, it can be concluded that the modification
of the 1-phosphate group of H. pylori lipid A requires two
enzymatic steps as follows: 1) removal of the 1-phosphate group
by a specific phosphatase (Hp0021), and 2) addition of a pEtN
unit directly to the glucosamine disaccharide backbone by a
pEtN transferase (Hp0022).
Lipid A Transport across the Inner Membrane Is Required for
Hp0021-catalyzed 1-Dephosphorylation—Kdo2-lipid A is synthesized on the cytoplasmic face of the inner membrane followed by the addition of the core oligosaccharide. The coreKdo2-lipid A molecule is then transported across the inner
membrane by the essential flippase, MsbA. As described previously by Doerrler et al. (67), MsbA-dependent transport of
lipid A across the inner membrane is lost in the E. coli temperature-sensitive mutant WD2 by shifting cells from 30 to
44 °C for 30 min during the mid-log phase of growth. We have
confirmed that Hp0021 1-phosphatase activity is localized to
the inner membrane fraction based upon isopycnic density
gradient separation of membranes from NovaBlue(DE3)-expressing Hp0021 (data not shown). By using WD2, we investigated whether or not the active site of Hp0021 was facing the
periplasmic or cytosolic face of the inner membrane.
E. coli WD2 and its parent strain W3110A were transformed
with either pWSK29 or pWSHp0021 (pWSK29 expressing
Hp0021). Cells were grown at the permissive temperature of
30 °C until A600 of 0.6 – 0.7, following a temperature shift to 44 °C
for 30 min, to inactivate MsbA-dependent lipid A transport. Cells
were then labeled with 4 Ci/ml 32Pi for 20 min, and the newly
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FIG. 8. MALDI-TOF mass spectrometry of lipid A from E. coli expressing the H. pylori lipid A 1-phosphatase and pEtN transferase
genes. The lipid A of E. coli NovaBlue(DE3) containing either pDuet-1 (A), pHp0021duet (B), pHp0022duet (C), or pHp0021/Hp0022 (D) was
isolated and fractionated by DEAE-cellulose chromatography using published protocols (38). The lipid A samples were analyzed by MALDI-TOF
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FIG. 9. Removal of the lipid A 1-phosphate group by Hp0021 is
dependent upon the lipid A transporter, MsbA. E. coli strains
WD2 and W3110A containing either pWSK29 or pWSHp0021 were
temperature-shifted to 44 °C for 30 min. Newly synthesized lipids were
32
P-labeled for 20 min following temperature shift, and the lipid A was
isolated as described under “Experimental Procedures.” Lipid A species
from the indicated strains were separated by TLC using the solvent
chloroform, pyridine, 88% formic acid, water (50:50:16:5, v/v) and visualized by PhosphorImaging.

synthesized 32P-labeled lipid A species was isolated and separated by TLC. At 30 °C, W3110A (temperature-sensitive control)
and WD2 synthesized solely 1-dephosphorylated lipid A species
(Fig. 9) when containing the plasmid pWSHp0021. Shifting
W3110A expressing Hp0021 to 44 °C had no effect on production
of 1-dephosphorylated lipid A. However, inactivation of MsbA at
44 °C in WD2/pWSHp0021 resulted in the loss of 1-dephosphorylation (Fig. 9), indicating that the H. pylori 1-phosphatase
active site is oriented toward the periplasm. Recently, Wang et al.
(55) showed a similar result using a lipid A 1-phosphatase cloned
from Franciscella novicida.
DISCUSSION

The LPS of H. pylori is distinct from enterobacterial LPS in
having a unique lipid A structure and many types of O-antigen
polysaccharide, including Lewis antigen structures (23–25, 56,
57). H. pylori lipid A shows very low endotoxic properties (14,
19, 20) and has longer fatty acyl chains and fewer phosphate
residues (Fig. 1C) (13, 14, 19). A number of Gram-negative
bacteria modify the phosphate groups of their lipid A (58).
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Recently, Lee et al. (72) has shown that addition of pEtN to the
1-phosphate of S. enterica is important for resistance to the
antimicrobial peptide polymyxin. In the case of H. pylori, the
C-1 hydroxyl group of the proximal glucosamine sugar is derivatized with pEtN (13, 14, 19) (Fig. 1C). We report here that
the pEtN moiety found at the C-1 position of H. pylori lipid A
arises from the removal of the lipid A 1-phosphate group followed by the addition of pEtN to form a glycosidic phosphodiester linkage.
Recently, Karbarz et al. (46) reported the cloning of a membrane-bound enzyme, LpxE, which removes the 1-phosphate
group of R. leguminosarum lipid A. In R. leguminosarum, the
removal of the 1-phosphate group is followed by oxidation of the
proximal sugar by the outer membrane enzyme LpxQ (59, 60).
LpxE shares sequence homology to E. coli PgpB (45, 47, 48),
primarily in the conserved active site motif (61) found in many
lipid phosphatases. Examination of the COG data base shows
that H. pylori strain 26695 contains four putative PgpB orthologs designated as Hp0021, Hp0350, Hp0851, and Hp1580.
We had already detected the presence of a 1-phosphatase activity in membranes of H. pylori (Fig. 2). However, by assaying
membranes of E. coli expressing the individual H. pylori PgpB
orthologs using key 32P-labeled lipid A precursors as substrates, we showed that Hp0021 functions as a lipid A 1-phosphatase (Fig. 3).
Both LpxE and Hp0021 have multitransmembrane domains
and, like other lipid phosphatases, require detergent for activity (45, 61, 62). Hp0021 was capable of removing the 1-phosphate group from various lipid A precursors, including mature
Kdo2-lipid A (Figs. 4 and 6). Membranes from wild type
H. pylori strains 26695 and J99 catalyzed the 1-dephosphorylation of lipid IVA at a specific activity of ⬃1.4 nmol/min/mg,
whereas Rhizobium membranes showed a specific activity of
only 0.014 nmol/min/mg. In comparison, membranes of E. coli
overexpressing Hp0021 showed a specific activity of 170 nmol/
min/mg resulting in more than a 100-fold increase over wild
type levels. Most interestingly, expression of Hp0021 in E. coli
K12 strains NovaBlue(DE3) (Fig. 7 and Fig. 8B) and
HMS174(DE3) (Fig. 5) resulted in nearly 100% production of
1-dephosphorylated lipid A with no significant effects on bacterial growth, suggesting that removal of the 1-phosphate
group of lipid A is not toxic to growth under normal laboratory
conditions. The ability to generate E. coli strains lacking the
1-phosphate group of lipid A may prove to be useful for the
development of specific vaccines. Monophosphorylated lipid A
has been shown to be an effective adjuvant retaining the immunostimulatory properties of LPS but with greatly reduced
toxic effects (63– 65).
We also have presented data suggesting that Hp0022 functions as the H. pylori lipid A pEtN transferase. However, enzymatic data using defined substrates will be needed to confirm
the function of Hp0022. The hp0021 and hp0022 genes appear
to form a typical prokaryotic operon because the individual
open reading frames are separated by only 10 bp, and the genes
are unidirectionally transcribed beginning with hp0022.
Hp0022 shares homology with the recently described LptA that
is predicted to serve as a putative lipid A pEtN transferase in
N. meningitidis (53). Based upon topology prediction programs
(see sosui.proteome.bio.tuat.ac.jp/sosuiframe0.html), Hp0022
has six transmembrane regions with the soluble C-terminal

mass spectrometry in the negative-ion mode. Although mass spectrometry data was acquired on lipids eluting in all salt fractions from the DEAE
column, only the most representative data is shown for comparison. Data shown in A and C are from lipid A species found to elute in the 240 mM
salt fraction, whereas data shown in B and D are from lipids eluting in the 60 mM salt fraction (see “Experimental Procedures”). The molecular
weights of E. coli hexa-acylated bisphosphate lipid A, 1-dephosphorylated-lipid A, and 1-pEtN-lipid A are 1798.4, 1719.4, and 1841.4, respectively.
E shows the positive ion spectrum of lipid A obtained from NovaBlue(DE3) containing pHp0021duet.
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FIG. 10. Proposed topology of the cleavage and modification of the 1-phosphate group of H. pylori lipid A. After assembly of Kdo2-lipid
A bearing the core oligosaccharide (core-lipid A), the macromolecule is transported across the inner membrane by the ABC transporter, MsbA (28,
67). In H. pylori, the 1-phosphate group of the lipid A domain can then be removed by a specific phosphatase Hp0021. This is followed by the
addition of a pEtN unit directly to the glucosamine disaccharide backbone catalyzed by the lipid A pEtN transferase, Hp0022. The predicted
membrane topology of Hp0021 and Hp0022 was determined using the program SOSUI (sosui.proteome.bio.tuat.ac.jp/sosuiframe0.html) (75, 76).

region predicted to be located in the periplasmic region of the
cell envelope. Expression of Hp0022 alone in an E. coli K12
strain did not result in modification to the bisphosphorylated
E. coli lipid A structure. However, expression of both Hp0021
and Hp0022 together using a dual expression system resulted
in the production of a lipid A species modified at the C-1
position with pEtN (Figs. 7 and 8). These findings confirmed
our hypothesis that H. pylori 1-phosphate group modification is
a two-step process. One would expect a similar mechanism to
occur in the Gram-negative pathogen Porphyromonas gingivalis, the lipid A of which also contains a pEtN rather than a
pyrophosphoethanolamine group at the 1-position. BLASTp
analysis shows a distant homolog (E value ⬍10⫺20) of Hp0022
in P. gingivalis. However, there are no significant homologs of
Hp0021 (E value ⬍10⫺4 using BLASTp) in the sequenced genome of P. gingivalis W83. This is not too surprising considering Hp0021 is only distantly related to Rhizobium LpxE and is
not detected as a H. pylori homolog using BLASTp. Therefore,
further biochemical investigation will be required to determine
whether P. gingivalis uses a mechanism similar to that of
H. pylori during the modification of its lipid A.
With our evidence that Hp0021 phosphatase activity in
E. coli is MsbA-dependent, we propose a periplasmic model for
the modification of the H. pylori lipid A 1-phosphate group (Fig.
10). Following synthesis of bisphosphorylated Kdo2-lipid A via
the constitutive pathway, the lipid is flipped across the inner
membrane by the ABC transporter MsbA (28, 39, 66 – 68).
Hp0021, an inner membrane phosphatase, then removes the
proximal phosphate group from H. pylori lipid A. This is followed by addition of a pEtN moiety to the disaccharide backbone catalyzed by the lipid A pEtN transferase Hp0022. It is
very likely that the glycerophospholipid PtdEtn serves as the
donor substrate because E. coli that are unable to synthesize
PtdEtn are unable to modify their lipid A with pEtN residues
(69). On the whole, modification of the lipid A structure in the
extracytoplasmic compartments has become a theme in the
biosynthesis of lipid A given that a number of lipid A-modifying
enzymes are outer membrane proteins (30, 40) or have active

sites facing the periplasmic region (55, 69 –72).
Our work has corroborated the structure reported previously
for H. pylori lipid A (13–15). We are currently in the process of
constructing H. pylori mutants lacking functional copies of
hp0021 and hp0022. These mutants will help us determine the
importance of pEtN addition to the C-1 hydroxyl group of
H. pylori lipid A during infection. Also, because none of the
H. pylori PgpB orthologs showed lipid A 4⬘-phosphatase activity, we are actively trying to identify the structural gene encoding this enzyme. Changing the charge of the lipid A domain
of H. pylori LPS most likely aids the bacterium in establishing
the prolonged chronic infections seen with this organism by
providing resistance to cationic antimicrobial peptides and reducing the endotoxic principle of H. pylori LPS.
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